CA3050106A1 - Apoc-ii mimetic peptides - Google Patents

Apoc-ii mimetic peptides Download PDF

Info

Publication number
CA3050106A1
CA3050106A1 CA3050106A CA3050106A CA3050106A1 CA 3050106 A1 CA3050106 A1 CA 3050106A1 CA 3050106 A CA3050106 A CA 3050106A CA 3050106 A CA3050106 A CA 3050106A CA 3050106 A1 CA3050106 A1 CA 3050106A1
Authority
CA
Canada
Prior art keywords
peptide
apoc
helix
amino acid
fatty acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3050106A
Other languages
English (en)
French (fr)
Inventor
Alan Thomas REMALEY
Soumitra Shanker Ghosh
Madhav N. Devalaraja
Chih-Hung Lo
Denis O. Sviridov
Anna WOLSKA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
US Department of Health and Human Services
Original Assignee
Corvidia Therapeutics Inc
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corvidia Therapeutics Inc, US Department of Health and Human Services filed Critical Corvidia Therapeutics Inc
Publication of CA3050106A1 publication Critical patent/CA3050106A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722—Plasma globulins, lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA3050106A 2017-01-19 2018-01-19 Apoc-ii mimetic peptides Pending CA3050106A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762448358P 2017-01-19 2017-01-19
US62/448,358 2017-01-19
US201762476535P 2017-03-24 2017-03-24
US201762476531P 2017-03-24 2017-03-24
US62/476,535 2017-03-24
US62/476,531 2017-03-24
PCT/US2018/014532 WO2018136803A1 (en) 2017-01-19 2018-01-19 Apoc-ii mimetic peptides

Publications (1)

Publication Number Publication Date
CA3050106A1 true CA3050106A1 (en) 2018-07-26

Family

ID=62908746

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3050106A Pending CA3050106A1 (en) 2017-01-19 2018-01-19 Apoc-ii mimetic peptides

Country Status (14)

Country Link
US (2) US11136372B2 (enExample)
EP (1) EP3571216A4 (enExample)
JP (2) JP7353973B2 (enExample)
KR (1) KR102700862B1 (enExample)
CN (1) CN110831957B (enExample)
AU (1) AU2018210404B2 (enExample)
BR (1) BR112019014707A2 (enExample)
CA (1) CA3050106A1 (enExample)
IL (2) IL268093B2 (enExample)
MX (1) MX2019008529A (enExample)
NZ (1) NZ755599A (enExample)
SG (2) SG10201911974UA (enExample)
TW (2) TW202130652A (enExample)
WO (1) WO2018136803A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11136372B2 (en) 2017-01-19 2021-10-05 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services ApoC-II mimetic peptides

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240309065A1 (en) * 2021-06-23 2024-09-19 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Short apoc-ii mimetic peptides and methods of use
US20250304622A1 (en) * 2022-05-05 2025-10-02 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Short apolipoprotein e mimetic peptides and methods of use
WO2024036145A1 (en) * 2022-08-07 2024-02-15 Protean Bio, Inc. Peptides for beta-cell survival and insulin production

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
WO1998009602A2 (en) * 1996-09-05 1998-03-12 The Uab Research Foundation Anti-atherosclerotic peptides and a transgenic mouse model of atherosclerosis
CA2460787A1 (en) 2001-09-28 2003-04-03 Esperion Therapeutics, Inc. Prevention and treatment of restenosis by local administration of drug
US7220576B2 (en) * 2002-01-07 2007-05-22 Lifesensors, Inc. Methods and compositions for protein expression and purification
US7691965B2 (en) * 2002-05-08 2010-04-06 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
JP2007504285A (ja) * 2003-01-17 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド Ｎ−シクロヘキシルアミノカルボニルベンゼンスルホンアミド誘導体
CA2555409A1 (en) * 2004-02-19 2005-09-01 Banyu Pharmaceutical Co., Ltd. Novel sulfone amide derivative
EP1771473B1 (en) 2004-07-16 2012-12-26 Trustees Of Tufts College Apolipoprotein a1 mimetics and uses thereof
JP5143729B2 (ja) * 2005-06-29 2013-02-13 ハダジット メディカル リサーチ サービシズ アンド ディベラップメント リミテッド インスリン抵抗性及び２型糖尿病の予防のためのプロテインキナーゼｃ阻害剤
WO2008039843A2 (en) * 2006-09-26 2008-04-03 Lipid Sciences, Inc. Novel peptides that promote lipid efflux
WO2009097584A1 (en) 2008-01-30 2009-08-06 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
WO2009129263A1 (en) * 2008-04-15 2009-10-22 The Government Of The Usa As Represented By The Secretary Of The Department Of Health & Human Serv. Peptides promoting lipid efflux via abca1 and activating a lipoprotein lipase
CN102753576A (zh) * 2009-09-30 2012-10-24 首尔大学教产学协力团 载脂蛋白a-1模拟肽以及包含其的用于治疗高血脂及高血脂相关疾病的治疗剂
CA2888657C (en) 2012-11-06 2022-05-03 Les Hopitaux Universitaires De Geneve Mimetic peptides
MX2019008529A (es) 2017-01-19 2020-02-07 Us Health Peptidos mimeticos de apolipoproteina c-ii (apoc-ii).
EA201991491A1 (ru) 2017-03-24 2019-12-30 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сервисис Миметические пептиды apoc-ii

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11136372B2 (en) 2017-01-19 2021-10-05 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services ApoC-II mimetic peptides
US11827690B2 (en) 2017-01-19 2023-11-28 Novo Nordisk Inc. ApoC-II mimetic peptides

Also Published As

Publication number Publication date
KR102700862B1 (ko) 2024-08-30
IL268093B2 (en) 2024-07-01
JP2023116739A (ja) 2023-08-22
JP2020511425A (ja) 2020-04-16
AU2018210404B2 (en) 2022-01-27
US11827690B2 (en) 2023-11-28
US20210324043A1 (en) 2021-10-21
NZ755599A (en) 2022-12-23
SG11201906422VA (en) 2019-08-27
TWI788323B (zh) 2023-01-01
US11136372B2 (en) 2021-10-05
KR20190121305A (ko) 2019-10-25
IL268093A (en) 2019-09-26
EP3571216A1 (en) 2019-11-27
SG10201911974UA (en) 2020-02-27
TW201835097A (zh) 2018-10-01
TW202130652A (zh) 2021-08-16
AU2018210404A1 (en) 2019-08-08
WO2018136803A8 (en) 2019-08-01
US20200140522A1 (en) 2020-05-07
MX2019008529A (es) 2020-02-07
WO2018136803A1 (en) 2018-07-26
BR112019014707A2 (pt) 2020-04-07
CN110831957B (zh) 2024-02-09
JP7353973B2 (ja) 2023-10-02
CN110831957A (zh) 2020-02-21
IL268093B1 (en) 2024-03-01
IL279831A (en) 2021-03-01
EP3571216A4 (en) 2020-11-04

Similar Documents

Publication Publication Date Title
US11827690B2 (en) ApoC-II mimetic peptides
CN107074923B (zh) Apoe模拟肽及对清除血浆胆固醇的较高效力
US9815869B2 (en) SP-B and SP-C peptides, synthetic lung surfactants, and use thereof
JP2019089834A (ja) アポリポタンパク質模倣体及びその使用
JP2007534612A (ja) 高コレステロール血症の治療のためのコレステロール逆輸送メディエータ
US20240309065A1 (en) Short apoc-ii mimetic peptides and methods of use
EA042134B1 (ru) МИМЕТИЧЕСКИЕ ПЕПТИДЫ apoC-II
US20170305981A1 (en) Synthetic peptides
WO2014004467A1 (en) Selective cartilage therapy
HK1242718A1 (en) Apoe mimetic peptides and higher potency to clear plasma cholesterol

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220907

EEER Examination request

Effective date: 20220907

EEER Examination request

Effective date: 20220907

EEER Examination request

Effective date: 20220907